Bulletin
Investor Alert

BioNTech SE ADR

NAS: BNTX

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 15, 2021, 7:59 p.m.

/zigman2/quotes/214419716/composite

$

246.50

Change

-1.18 -0.48%

Volume

Volume 26,853

Quotes are delayed by 20 min

/zigman2/quotes/214419716/composite

Today's close

$ 250.33

$ 247.68

Change

-2.65 -1.06%

Day low

Day high

$245.28

$252.80

Open

52 week low

52 week high

$75.35

$464.00

Open

Company Description

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates incl...

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Valuation

P/E Current

3,591.07

P/E Ratio (with extraordinary items)

13.19

P/E Ratio (without extraordinary items)

1,107.61

Price to Sales Ratio

36.85

Price to Book Ratio

11.73

Enterprise Value to EBITDA

-38.77

Enterprise Value to Sales

1.08

Total Debt to Enterprise Value

0.02

Efficiency

Revenue/Employee

283,276.00

Income Per Employee

8,926.00

Receivables Turnover

4.86

Total Asset Turnover

0.29

Liquidity

Current Ratio

2.70

Quick Ratio

2.60

Cash Ratio

2.00

Profitability

Gross Margin

87.76

Operating Margin

-55.27

Pretax Margin

-30.23

Net Margin

3.15

Return on Assets

0.93

Return on Equity

1.55

Return on Total Capital

-23.29

Return on Invested Capital

1.34

Capital Structure

Total Debt to Total Equity

17.51

Total Debt to Total Capital

14.90

Total Debt to Total Assets

10.36

Long-Term Debt to Equity

16.84

Long-Term Debt to Total Capital

14.33

Officers and Executives

Name Age Officer Since Title
Mr. Helmut Jeggle 50 - Chairman-Supervisory Board
Dr. Ugur Sahin 54 2008 Chief Executive Officer
Dr. Sierk Pötting 47 2014 Chief Operating & Financial Officer
Mr. Jens Holstein 56 2021 Chief Financial Officer
Dr. Özlem Türeci 52 2008 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/bntx

MarketWatch News on BNTX

  1. Moderna Stock Falls on Report FDA Delays Clearing Its Vaccine for Adolescents

    1:50 p.m. Today

    - Sabrina Escobar

  2. Bitcoin Is Jumping. A Futures ETF May Finally Be Here.

    6:37 a.m. Today

  3. Moderna Booster Gets Nod From FDA Panel

    5:00 p.m. Oct. 14, 2021

    - Josh Nathan-Kazis

  4. J&J Booster Shot May Bolster Immune Response, FDA Says

    4:08 p.m. Oct. 13, 2021

    - Sabrina Escobar

  5. FDA Panel to Debate J&J and Moderna Boosters

    6:32 a.m. Oct. 13, 2021

    - Josh Nathan-Kazis

  6. Merck Submits Covid Pill to FDA for Emergency Approval

    8:27 a.m. Oct. 11, 2021

    - Jack Denton

  7. Loading more headlines...
/news/nonmarketwatch/company/us/bntx

Other News on BNTX

  1. Canada-U.S. Border: Everything You Need to Know About Reopening, Travel

    8:24 p.m. Today

    - Paul Vieira

  2. Should I Get a Covid-19 Vaccine Booster Shot? What to Know

    5:25 p.m. Today

    - Felicia Schwartz

  3. FDA weighs lowering age limit for Pfizer/ BioNTech COVID-19 booster shot - Reuters

    4:34 p.m. Today

    - Seeking Alpha

  4. Moderna Vaccine for Adolescents Delayed for FDA Review

    4:28 p.m. Today

    - Felicia Schwartz

  5. J&J Covid-19 Booster Shot Endorsed by FDA Advisers

    2:54 p.m. Today

    - Peter Loftus

  6. U.S. to Lift Restrictions for International Travelers

    12:49 p.m. Today

    - Ken Thomas

  7. FDA decision on Moderna COVID-19 shot for adolescents likely to get delayed - WSJ

    12:46 p.m. Today

    - Seeking Alpha

  8. BioNTech's Pipeline, Children's Vaccines, And Comirnaty Demand

    10:49 a.m. Today

    - Seeking Alpha

  9. Pfizer and BioNTech submit data to EMA for COVID-19 vaccine for children ages 5-11

    10:25 a.m. Today

    - Seeking Alpha

  10. Pfizer's Next mRNA Vaccine Candidate Goes Beyond COVID-19

    6:55 a.m. Today

    - Motley Fool

  11. 3 Top Stocks Under $100

    6:45 a.m. Today

    - Motley Fool

  12. IBB: Healthcare Dashboard For October

    8:24 p.m. Oct. 14, 2021

    - Seeking Alpha

  13. Best Single Trading Day in Months for Dow, Nasdaq, S&P

    6:04 p.m. Oct. 14, 2021

    - Zacks.com

  14. Why Moderna Stock Trounced the Market Today

    5:45 p.m. Oct. 14, 2021

    - Motley Fool

  15. Moderna Booster Shot Backed by FDA Advisory Panel

    4:34 p.m. Oct. 14, 2021

    - Felicia Schwartz

  16. More Americans getting COVID boosters than first doses - CNBC

    10:01 a.m. Oct. 14, 2021

    - Seeking Alpha

  17. Loading more headlines...

At a Glance

BioNTech SE

An der Goldgrube 12

Mainz, Rheinland-Pfalz 55131

Phone

49 613190840

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$549.84M

Net Income

$17.33M

2020 Sales Growth

352.4%

Employees

1,941

/news/pressrelease/company/us/bntx

Press Releases on BNTX

  1. J&J Applies for COVID Booster Nod

    10:43 a.m. Oct. 5, 2021

    - Baystreet.ca

  2. Biontech Se BNTX Trading Advice

    10:22 a.m. Oct. 5, 2021

    - Stock Traders Daily

  3. When the Price of Biontech Se BNTX Talks, People Listen

    4:07 p.m. Sept. 25, 2021

    - Stock Traders Daily

  4. Pfizer Touts Safety of COVID Vaccine for Kids

    10:12 a.m. Sept. 20, 2021

    - Baystreet.ca

  5. Loading more headlines...
Link to MarketWatch's Slice.